Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401).

A Ashley Odai-Afotey (Dana-Farber Cancer Institute, Boston, MA) L Linda Mackie McCall (Alliance Statistics and Data Management Center, Duke University, Durham, NC) K Karla V. Ballman (From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...) C Chao Cao P Pamela Jean Goodwin (Mount Sinai Hospital-Breast Medical Oncology, Toronto, ON, Canada) V Vanessa Bernstein (BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada) L Linda Delahanty D Dawn L. Hershman (Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center New York New York USA) J Judith O. Hopkins (Southeast Clinical Oncology Research Consortium and NCORP, Winston Salem, NC) E Erica L. Mayer E Electra D. Paskett P Patricia Spears (UNC Patient Advocates for Research Council, Raleigh, NC) V Vered Stearns (Weill Cornell Medical Center, New York, NY) A Anna Weiss J Julia R. White (University of Kansas Medical Center Comprehensive Cancer Center, Kansas City) T Thomas Wadden (Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia) E Eric P. Winer (Yale School of Medicine, New Haven, CT) L Lisa A. Carey (Lineberger Comprehensive Cancer Center, UNC Health, Chapel Hill, NC) A Ann H. Partridge (Dana–Farber Cancer Institute, Harvard Medical School, Boston) J Jennifer A. Ligibel (Dana-Farber Cancer Institute, Boston, MA)

Abstract

1586 Background: Black and Hispanic breast cancer (BC) survivors have a higher prevalence of obesity and experience less success with weight loss interventions (WLI) than White BC survivors. The BWEL trial (Alliance A011401; NCT02750826) is a phase III randomized trial evaluating the impact of a 2-year telephone-based WLI on invasive disease-free survival in participants (pts) with stage II-III HER2-negative BC and a BMI ≥ 27 kg/m 2 . At 12-months, the WLI induced significant weight loss across demographic factors, including race and ethnicity. However, Black and Hispanic pts lost less weight and completed fewer calls than White pts. Here, we evaluate intervention adherence, engagement and tool utilization in BWEL pts by race and ethnicity. Methods: BWEL randomized pts to a WLI plus health education (HE) or HE alone. WLI pts received semi-structured telephone-based health coaching, delivered in English or Spanish, and received an activity monitor and wireless scale. Pts self-reported race and ethnicity. Mean values for call duration, call density (time to complete the initial 12-week intensive intervention phase), intervention attrition, and frequency of Fitbit use and weight tracking over 12-months were compared by race and ethnicity, comparing least squares means with Tukey-Kramer adjustment for multiple comparisons with adjusted p-values. Results: Of 3181 pts randomized to the study between 08/2016 and 02/2021, 1591 pts were allocated to the WLI arm. 80.5% of pts were White, 12.8% Black, and 7.1% Hispanic. Average BMI was 34.5 (±5.7) kg/m2. Compared to White pts, Black pts had fewer days of Fitbit usage (113.6 vs. 159.8, p<0.0001) and weight tracking (77.9 vs. 135.6 days, p< 0.0001). Hispanic pts had fewer days of Fitbit usage (108.8 vs. 154.9, p= 0.001) and weight tracking (87 vs. 129.5 days, p=0.0002) compared to non-Hispanic pts. There were no differences in attrition rate, average call duration, or call density by race or ethnicity. Conclusions: In a phase III WLI trial, engagement with tools designed to support weight loss was significantly lower in Black and Hispanic pts. Future work is needed to explore ways to enhance engagement and improve weight loss outcomes for racial and ethnic minority pts. Support: U10CA180821, U10CA180882, UG1CA189823; https://acknowledgments.alliancefound.org . Clinical trial information: NCT02750826 . Measure of engagement Race Ethnicity WhiteN=1281 BlackN=204 p-value Non-HispanicN=1459 HispanicN=113 p-value Withdrew from intervention n (%) 58 (4.5%) 13 (6.4%) 0.56 70 (4.8%) 6 (5.3%) 0.51 Call Duration (min)Mean (SD) 34.5 (7.6) 34.6 (9.1) 0.99 34.6 (7.8) 33.3 (7.9) 0.25 Call density(weeks)Mean (SD) 14.2 (7.2) 14.2 (8.8) 0.99 14.2 (7.3) 14.2 (9.7) 0.99 Days of Fitbit UseMean (SD) 159.8 (132.2) 113.6 (124.7) < 0.0001 154.9 (131.8) 108.8 (125.7) 0.001 Days of weight trackingMean (SD) 135.6 (109.5) 77.9 (87.5) < 0.0001 129.5 (108.8) 87 (96.5) 0.0002

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 1586-1586
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

A

Ashley Odai-Afotey

Dana-Farber Cancer Institute, Boston, MA

L

Linda Mackie McCall

Alliance Statistics and Data Management Center, Duke University, Durham, NC

K

Karla V. Ballman

From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...

C

Chao Cao

P

Pamela Jean Goodwin

Mount Sinai Hospital-Breast Medical Oncology, Toronto, ON, Canada

V

Vanessa Bernstein

BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

L

Linda Delahanty

D

Dawn L. Hershman

Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center New York New York USA

J

Judith O. Hopkins

Southeast Clinical Oncology Research Consortium and NCORP, Winston Salem, NC

E

Erica L. Mayer

E

Electra D. Paskett

P

Patricia Spears

UNC Patient Advocates for Research Council, Raleigh, NC

V

Vered Stearns

Weill Cornell Medical Center, New York, NY

A

Anna Weiss

J

Julia R. White

University of Kansas Medical Center Comprehensive Cancer Center, Kansas City

T

Thomas Wadden

Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia

E

Eric P. Winer

Yale School of Medicine, New Haven, CT

L

Lisa A. Carey

Lineberger Comprehensive Cancer Center, UNC Health, Chapel Hill, NC

A

Ann H. Partridge

Dana–Farber Cancer Institute, Harvard Medical School, Boston

J

Jennifer A. Ligibel

Dana-Farber Cancer Institute, Boston, MA